3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
93
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
33
Carcinoma, Renal Cell
24
Neoplasm Metastasis
16
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
12
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Advanced Cancer
9
Squamous Cell Carcinoma of Head and Neck
8
Uveal Melanoma
7
Stomach Neoplasms
7
Skin Neoplasms
7
Mesothelioma
7
Kidney Neoplasms
7
Carcinoma, Transitional Cell
7
Recurrence
6
Pancreatic Neoplasms
6
Liver Neoplasms
6
Triple Negative Breast Neoplasms
5
Sarcoma
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Solid Tumor
4
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
7
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
derazantinib
2
Leucovorin
2
trametinib
1
tislelizumab
1
silmitasertib
1
seribantumab
1
pertuzumab
1
olutasidenib
1
galactomannan
1
exatecan
1
durvalumab
1
becatecarin
1
Tegafur
1
Standard of Care
1
S 1 (combination)
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microscopy, Confocal
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bile Duct Neoplasms
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts